Product Pathways - Growth Factors/Cytokines
Human Interleukin-17F (hIL-17F) #8906
|8906LF||100 µg (Carrier Free)||---||In Stock||---|
|8906LC||100 µg (With Carrier)||---||In Stock||---|
|8906SC||25 µg (With Carrier)||---||In Stock||---|
|8906SF||25 µg (Carrier Free)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant human IL-17F (hIL-17F) Arg31-Gln163 (Accession #NP_443104) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant hIL-17F contains no "tags" and the nonglycosylated protein has a calculated MW of 14,903. DTT-reduced protein migrates as a 22 kDa polypeptide. Lower mobility in SDS-PAGE is due to glycosylation. The non-reduced cystine-linked homodimer migrates as a 38 kDa protein. The expected amino-terminal RKIPK of recombinant hIL-17F was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-17F. All lots are greater than 98% pure.
The bioactivity of recombinant hIL-17F was determined by its ability to induce mouse IL-6 production by 3T3 MEFs WT. The ED50 of each lot is between 30-80 ng/ml.
The purity of recombinant hIL-17F was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-17F and staining overnight with Coomassie Blue.
Less than 0.01 ng endotoxin/1 μg hIL-17F.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-17F. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
IL-17F is a cystine-linked homodimeric pro-inflammatory cytokine produced by TH17 cells, a distinct CD4+ T cell subset (1). IL-17F induces the production of pro-inflammatory cytokines, antimicrobial peptides, and neutrophil chemoattractants such as IL-6, β-defensin, IL-8, CXCL1, and CXCL6 (1,2). As a result, IL-17F may provide an important link between adaptive and the innate immunity. IL-17F binds with high affinity to IL-17RC, expressed primarily in non-hematopoietic tissues, and with lesser affinity to IL-17RA, which is expressed in hematopoietic tissues (3). IL-17F binding activates the ERK1/2 MAP kinase and NF-κB pathways (1,4). IL-17F appears to be involved in mucosal immunity against bacterial infections and possibly some autoimmune conditions (1,5,6).
- Kolls, J.K. and Lindén, A. (2004) Immunity 21, 467-76.
- Liang, S.C. et al. (2006) J Exp Med 203, 2271-9.
- Kuestner, R.E. et al. (2007) J Immunol 179, 5462-73.
- Kawaguchi, M. et al. (2002) J Biol Chem 277, 15229-32.
- Zrioual, S. et al. (2009) J Immunol 182, 3112-20.
- Ishigame, H. et al. (2009) Immunity 30, 108-19.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.